Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Tzu Tai

Showing results (131-140 of 211) with videos related to

Pageof 22
Sort By:
Cancer Research|August 17, 2005
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistanceHiroshi Yasui, Teru Hideshima, Noopur Raje, et al.
Oncotarget|November 17, 2016
Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myelomaLihui Shi, Xiaoqi Qin, Huijun Wang, et al.
Blood|September 8, 2012
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibitionMichele Cea, Antonia Cagnetta, Mariateresa Fulciniti, et al.
Annals of Hematology|September 19, 2014
Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patientsGang An, Xiaoqi Qin, Chirag Acharya, et al.
Cancer Research|June 18, 2014
Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibitionNaoya Mimura, Teru Hideshima, Toshiyasu Shimomura, et al.
Blood|April 2, 2005
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myelomaHiroshi Yasui, Teru Hideshima, Makoto Hamasaki, et al.
Molecular Cancer Therapeutics|January 14, 2009
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivoRenate Burger, Steven Le Gouill, Yu-Tzu Tai, et al.
Frontiers in Immunology|September 14, 2020
Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma CellsChen Zhu, Zhili Song, Anlai Wang, et al.
Blood|September 11, 2014
Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche modelMichaela R Reagan, Yuji Mishima, Siobhan V Glavey, et al.
Blood|February 27, 2014
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myelomaYu-Tzu Tai, Patrick A Mayes, Chirag Acharya, et al.
Pageof 22

Showing results (131-140 of 211) with videos related to

Sort By:
Pageof 22
Cancer Research|August 17, 2005
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistanceHiroshi Yasui, Teru Hideshima, Noopur Raje, et al.
Oncotarget|November 17, 2016
Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myelomaLihui Shi, Xiaoqi Qin, Huijun Wang, et al.
Blood|September 8, 2012
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibitionMichele Cea, Antonia Cagnetta, Mariateresa Fulciniti, et al.
Annals of Hematology|September 19, 2014
Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patientsGang An, Xiaoqi Qin, Chirag Acharya, et al.
Cancer Research|June 18, 2014
Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibitionNaoya Mimura, Teru Hideshima, Toshiyasu Shimomura, et al.
Blood|April 2, 2005
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myelomaHiroshi Yasui, Teru Hideshima, Makoto Hamasaki, et al.
Molecular Cancer Therapeutics|January 14, 2009
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivoRenate Burger, Steven Le Gouill, Yu-Tzu Tai, et al.
Frontiers in Immunology|September 14, 2020
Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma CellsChen Zhu, Zhili Song, Anlai Wang, et al.
Blood|September 11, 2014
Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche modelMichaela R Reagan, Yuji Mishima, Siobhan V Glavey, et al.
Blood|February 27, 2014
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myelomaYu-Tzu Tai, Patrick A Mayes, Chirag Acharya, et al.
Pageof 22